- Home
- OPI vs LPTX Comparison
OPI vs LPTX Comparison
Compare OPI & LPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPI
- LPTX
- Stock Information
- Founded
- OPI 2009
- LPTX 2011
- Country
- OPI United States
- LPTX United States
- Employees
- OPI N/A
- LPTX 54
- Industry
- OPI Real Estate Investment Trusts
- LPTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- OPI Real Estate
- LPTX Health Care
- Exchange
- OPI Nasdaq
- LPTX Nasdaq
- Market Cap
- OPI 105.1M
- LPTX 99.5M
- IPO Year
- OPI 2009
- LPTX N/A
- Fundamental
- Price
- OPI $1.13
- LPTX $2.58
- Analyst Decision
- OPI Buy
- LPTX Strong Buy
- Analyst Count
- OPI 2
- LPTX 4
- Target Price
- OPI $4.30
- LPTX $8.63
- AVG Volume (30 Days)
- OPI 1.4M
- LPTX 423.2K
- Earning Date
- OPI 10-30-2024
- LPTX 11-13-2024
- Dividend Yield
- OPI 3.49%
- LPTX N/A
- EPS Growth
- OPI N/A
- LPTX N/A
- EPS
- OPI N/A
- LPTX N/A
- Revenue
- OPI $517,514,000.00
- LPTX N/A
- Revenue This Year
- OPI N/A
- LPTX N/A
- Revenue Next Year
- OPI N/A
- LPTX N/A
- P/E Ratio
- OPI N/A
- LPTX N/A
- Revenue Growth
- OPI N/A
- LPTX N/A
- 52 Week Low
- OPI $1.06
- LPTX $1.68
- 52 Week High
- OPI $7.53
- LPTX $5.00
- Technical
- Relative Strength Index (RSI)
- OPI 18.01
- LPTX 37.04
- Support Level
- OPI $1.06
- LPTX $3.40
- Resistance Level
- OPI $1.35
- LPTX $2.90
- Average True Range (ATR)
- OPI 0.10
- LPTX 0.28
- MACD
- OPI -0.01
- LPTX -0.13
- Stochastic Oscillator
- OPI 8.70
- LPTX 6.29
About OPI Office Properties Income Trust of Beneficial Interest
Office Properties Income Trust is a United States-based real estate investment trust. Its property portfolio is mainly composed of single-tenant office buildings, as well as multitenant properties, which are leased to parties of high credit quality characteristics. Its largest tenant is the U.S. government, followed by other smaller government entities and corporations. The company's properties are spread across the United States. The company has only one segment which is direct ownership of real estate properties.
About LPTX Leap Therapeutics Inc.
Leap Therapeutics Inc is in developing targeted antibody therapies for cancer treatment, focusing on inhibiting tumor-promoting pathways, targeting cancer-specific cell surface molecules, and activating the immune system against cancer cells. The company's lead program, DKN-01, targets Dickkopf-related protein 1 (DKK1) and is in clinical trials for esophagogastric, gynecologic, and colorectal cancers. Their second program, FL-301, targets Claudin18.2-expressing cells. Additionally, the company has two preclinical antibody programs, FL-302 and FL-501, aimed at developing transformative cancer treatments. Operating as a single segment, the company's sole focus is on developing innovative drugs to address unmet needs in cancer therapy. .